763 related articles for article (PubMed ID: 21300471)
1. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
[TBL] [Abstract][Full Text] [Related]
2. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
3. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
5. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
7. The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Barr JG; Grundy PL
Br J Neurosurg; 2012 Dec; 26(6):818-22. PubMed ID: 22715955
[TBL] [Abstract][Full Text] [Related]
8. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
[TBL] [Abstract][Full Text] [Related]
9. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
10. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
De Bonis P; Anile C; Pompucci A; Fiorentino A; Balducci M; Chiesa S; Maira G; Mangiola A
Acta Neurochir (Wien); 2012 Aug; 154(8):1371-8. PubMed ID: 22718138
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
[TBL] [Abstract][Full Text] [Related]
15. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme.
Smith KA; Ashby LS; Gonzalez LF; Brachman DG; Thomas T; Coons SW; Battaglia M; Scheck A
J Neurosurg; 2008 Dec; 109 Suppl():106-17. PubMed ID: 19123896
[TBL] [Abstract][Full Text] [Related]
16. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A
J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047
[TBL] [Abstract][Full Text] [Related]
17. Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Salmaggi A; Duri S; Silvani A; Gaviani P; Milanesi I; Casali C; Di Meco F
Neurol Sci; 2011 Nov; 32 Suppl 2():S241-5. PubMed ID: 21983866
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Menei P; Metellus P; Parot-Schinkel E; Loiseau H; Capelle L; Jacquet G; Guyotat J;
Ann Surg Oncol; 2010 Jul; 17(7):1740-6. PubMed ID: 20443147
[TBL] [Abstract][Full Text] [Related]
19. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
20. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
